keyword
MENU ▼
Read by QxMD icon Read
search

protease inhibitors with lipoprotein in hiv

keyword
https://www.readbyqxmd.com/read/28857822/impact-of-protease-inhibitors-on-circulating-pcsk9-levels-in-hiv-infected-antiretroviral-na%C3%A3-ve-patients-from-the-anrs-copana-cohort
#1
Franck Boccara, Mathilde Ghislain, Laurence Meyer, Cecile Goujard, Cedric Le May, Corinne Vigouroux, Jean Philippe Bastard, Soraya Fellahi, Jacqueline Capeau, Ariel Cohen, Bertrand Cariou
OBJECTIVE: The study aims to assess the association between proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of low-density lipoprotein cholesterol (LDL-C) homeostasis, and HIV-related dyslipidaemia in a cohort of HIV+ patients under protease inhibitors (PI). METHODS: Plasma PCSK9 levels were measured in 103 HIV-positive patients (HIV+) before and after initiating PI-based antiretroviral therapy (ART), and in 90 HIV-negative controls (HIV-) matched for age and sex...
August 28, 2017: AIDS
https://www.readbyqxmd.com/read/28761616/cardiometabolic-risk-among-hiv-positive-ugandan-adults-prevalence-predictors-and-effect-of-long-term-antiretroviral-therapy
#2
Patrick Kazooba, Ivan Kasamba, Billy Nsubuga Mayanja, Joseph Lutaakome, Ivan Namakoola, Tino Salome, Pontiano Kaleebu, Paula Munderi
INTRODUCTION: We investigated the prevalence, predictors of and effect of Antiretroviral Therapy (ART) regimen on cardiometabolic risk among HIV-positive Ugandan adults at enrolment into a prospective cohort to study the Complications of Long-Term ART (CoLTART). METHODS: We collected data on cardiometabolic risk factors including dyslipidemia, hypertension, hyperglycemia, obesity and calculated the mean atherogenic index for Plasma (AIP) and 10 year Framingham risk score (FHS)...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28683645/substitution-of-nevirapine-or-raltegravir-for-protease-inhibitor-vs-rosuvastatin-treatment-for-the-management-of-dyslipidaemia-in-hiv-infected-patients-on-stable-antiretroviral-therapy-nevrast-study
#3
Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, Marco Borderi, Linda Bussini, Isabella Bon, Maria Carla Re, Pierluigi Viale
OBJECTIVES: An observational, prospective, cohort study was performed to compare efficacy and safety of a switch from ritonavir-boosted protease inhibitor (PI/r) to nevirapine or raltegravir with that of rosuvastatin addition to current antiretroviral therapy in HIV-infected patients with hyperlipidaemia. METHODS: All HIV-infected patients receiving a stable PI/r-based antiretroviral regimen, with persistently suppressed viremia, naïve to non-nucleoside analogues and to integrase strand transfer inhibitors, with mixed hyperlipidaemia, and who underwent a switch from PI/r to nevirapine (Group A) or raltegravir (Group B) or who started rosuvastatin at 10 mg daily (group C) with unchanged antiretroviral regimen were enrolled into the study...
July 6, 2017: Infectious Diseases
https://www.readbyqxmd.com/read/28665062/metabolic-complications-among-korean-patients-with-hiv-infection-the-korea-hiv-aids-cohort-study
#4
Dong Hyun Oh, Jin Young Ahn, Sang Il Kim, Min Ja Kim, Jun Hee Woo, Woo Joo Kim, Ji Hyeon Baek, Shin Woo Kim, Bo Youl Choi, Mi Hwa Lee, Ju Yeon Choi, Myung Guk Han, Chun Kang, June Myung Kim, Jun Yong Choi
Currently, metabolic complications are the most common problem among human immunodeficiency virus (HIV)-infected patients, with a high incidence. However, there have been very few studies regarding metabolic abnormalities published in Asia, especially in Korea. This cross-sectional study was performed to investigate the prevalence of and risk factors for metabolic abnormalities in 1,096 HIV-infected patients of the Korea HIV/AIDS cohort study enrolled from 19 hospitals between 2006 and 2013. Data at entry to cohort were analyzed...
August 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/28484508/cohort-profile-the-complications-of-long-term-antiretroviral-therapy-study-in-uganda-coltart-a-prospective-clinical-cohort
#5
Billy Nsubuga Mayanja, Ivan Kasamba, Jonathan Levin, Ivan Namakoola, Patrick Kazooba, Jackson Were, Pontiano Kaleebu, Paula Munderi
BACKGROUND: Antiretroviral therapy (ART) improves the survival and quality of life of HIV-positive individuals, but the effects of long-term ART use do eventually manifest. The Complications of Long-Term Antiretroviral Therapy cohort study in Uganda (CoLTART) was established to investigate the metabolic and renal complications of long-term ART use among Ugandan adults. We describe the CoLTART study set-up, aims, objectives, study methods, and also report some preliminary cross-sectional study enrolment metabolic and renal complications data analysis results...
2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/28473001/cohort-profile-the-complications-of-long-term-antiretroviral-therapy-study-in-uganda-coltart-a-prospective-clinical-cohort
#6
Billy Nsubuga Mayanja, Ivan Kasamba, Jonathan Levin, Ivan Namakoola, Patrick Kazooba, Jackson Were, Pontiano Kaleebu, Paula Munderi
BACKGROUND: Antiretroviral therapy (ART) improves the survival and quality of life of HIV-positive individuals, but the effects of long-term ART use do eventually manifest. The Complications of Long-Term Antiretroviral Therapy cohort study in Uganda (CoLTART) was established to investigate the metabolic and renal complications of long-term ART use among Ugandan adults. We describe the CoLTART study set-up, aims, objectives, study methods, and also report some preliminary cross-sectional study enrolment metabolic and renal complications data analysis results...
May 4, 2017: AIDS Research and Therapy
https://www.readbyqxmd.com/read/28420298/prevalence-of-metabolic-syndrome-in-hiv-infected-patients-naive-to-antiretroviral-therapy-or-receiving-a-first-line-treatment
#7
Leonardo Calza, Vincenzo Colangeli, Eleonora Magistrelli, Nicolo' Rossi, Elena Rosselli Del Turco, Linda Bussini, Marco Borderi, Pierluigi Viale
BACKGROUND: The combination antiretroviral therapy (cART) has dramatically improved the life expectancy of patients with HIV infection, but may lead to several long-term metabolic abnormalities. However, data about the frequency of metabolic syndrome (MS) in HIV-infected people vary considerably across different observational studies. METHODS: The prevalence of MS among HIV-infected patients was evaluated by a cross-sectional study conducted among subjects naive to cART or receiving the first antiretroviral regimen and referring to our Clinics from January 2015 to December 2015...
May 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/28391912/effects-of-atorvastatin-on-biomarkers-of-immune-activation-inflammation-and-lipids-in-virologically-suppressed-human-immunodeficiency-virus-1-infected-individuals-with-low-density-lipoprotein-cholesterol-130%C3%A2-mg-dl-aids-clinical-trials-group-study-a5275
#8
Daniel E Nixon, Ronald J Bosch, Ellen S Chan, Nicholas T Funderburg, Sally Hodder, Jordan E Lake, Michael M Lederman, Karin L Klingman, Judith A Aberg
BACKGROUND: Persistent immune activation and inflammation in virologically suppressed human immunodeficiency virus (HIV) infection are linked to excess cardiovascular risk. OBJECTIVE: To evaluate atorvastatin as a strategy to reduce cardiovascular risk. METHODS: A5275 was a multicenter, prospective, randomized, double-blind, placebo-controlled, cross-over pilot study of atorvastatin (10 mg/day for 4 weeks then 20 mg/day for 16 weeks) with a planned enrollment of 97 HIV-infected participants ≥18 years old, receiving boosted protease inhibitor-based antiretroviral therapy for ≥6 months, with plasma HIV-1 RNAs below limits of quantification ≥180 days, and fasting low-density lipoprotein (LDL) cholesterol ≥70 and <130 mg/dL...
January 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28361290/efficacy-and-safety-of-atazanavir-ritonavir-based-antiretroviral-therapy-for-hiv-1-infected-subjects-a-systematic-review-and-meta-analysis
#9
REVIEW
Amr Menshawy, Ammar Ismail, Abdelrahman Ibrahim Abushouk, Hussien Ahmed, Esraa Menshawy, Ahmed Elmaraezy, Mohamed Gadelkarim, Mohamed Abdel-Maboud, Attia Attia, Ahmed Negida
Atazanavir (ATZ) is a well-tolerated protease inhibitor that can be boosted with ritonavir (r) to treat infection with resistant strains of human immunodeficiency virus 1 (HIV-1). The aim of this meta-analysis was to compare the efficacy, safety, and metabolic effects of ATZ/r regimen versus commonly used antiretroviral drugs such as lopinavir (LPV) and darunavir (DRV) in HIV-1-infected patients. We searched PubMed, Scopus, Embase and Cochrane CENTRAL, using relevant keywords. Data were extracted from eligible randomized trials and pooled as risk ratios (RR) or standardized mean differences (SMD) in a meta-analysis model using RevMan software...
August 2017: Archives of Virology
https://www.readbyqxmd.com/read/28011249/lack-of-effects-of-statins-on-high-density-lipoprotein-subfractions-in-hiv-1-infected-patients-receiving-protease-inhibitors
#10
Randa Bittar, Élisabeth Aslangul, Philippe Giral, Lambert Assoumou, Marc-Antoine Valantin, Olga Kalmykova, Marie-Christine Federspiel, Corinne Cherfils, Dominique Costagliola, Dominique Bonnefont-Rousselot
BACKGROUND: We evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk. METHODS: The distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls...
February 2017: Comptes Rendus Biologies
https://www.readbyqxmd.com/read/27740537/hyperlipidaemia-in-hiv-infected-patients-on-lopinavir-ritonavir-monotherapy-in-resource-limited-settings
#11
Mitch M Matoga, Mina C Hosseinipour, Evgenia Aga, Heather J Ribaudo, Nagalingeswaran Kumarasamy, John Bartlett, Michael D Hughes
BACKGROUND: Cardiovascular disease (CVD) is an emerging concern for HIV-infected patients. Hyperlipidaemia is a risk factor for CVD and a complication of protease-inhibitor-based antiretroviral therapy, but little is known about its incidence and risk factors in treated patients in resource-limited settings (RLS). METHODS: We conducted a secondary analysis of ACTG A5230 trial in which HIV-infected adults from India, Malawi, Tanzania, Thailand and South Africa, with virological relapse on first-line therapy were initiated on lopinavir/ritonavir (LPV/r) monotherapy...
2017: Antiviral Therapy
https://www.readbyqxmd.com/read/27661466/changes-in-plasma-levels-of-oxidized-lipoproteins-and-lipoprotein-subfractions-with-atazanavir-raltegravir-darunavir-based-initial-antiviral-therapy-and-associations-with-common-carotid-artery-intima-media-thickness-actg-5260s
#12
Theodoros Kelesidis, Thuy Tien T Tran, Todd T Brown, Carlee Moser, Heather J Ribaudo, Michael P Dube, Otto O Yang, Grace A McComsey, James H Stein, Judith S Currier
BACKGROUND: The role of oxidized lipoproteins (high-density [HDLox] and low-density [LDLox]) and total lipoprotein particle (Lp) number and size in HIV-related cardiovascular disease (CVD) is unclear. The goal of this study was to evaluate changes of these biomarkers and their associations with rate of carotid intima media thickness progression over 3 years (ΔCIMT) in chronic HIV infection. METHODS: Prospective study of 234 HIV-infected antiretroviral treatment-naive participants without CVD who were randomized to receive tenofovir-emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir or raltegravir (RAL) and achieved plasma HIV-1 RNA <50 copies/ml by week 24 and thereafter...
2017: Antiviral Therapy
https://www.readbyqxmd.com/read/27603288/oxidized-lipoproteins-are-associated-with-markers-of-inflammation-and-immune-activation-in-hiv-1-infection
#13
Theodoros Kelesidis, Nicholas Jackson, Grace A McComsey, Xiaoyan Wang, David Elashoff, Michael P Dube, Todd T Brown, Otto O Yang, James H Stein, Judith S Currier
OBJECTIVE: The pathogenesis of immune dysfunction in chronic HIV-1 infection is unclear, and a potential role for oxidized lipids has been suggested. We hypothesize that both oxidized HDL and LDL (HDLox and LDLox) contribute to HIV-1-related immune dysfunction. STUDY: In the AIDS Clinical Trials Group A5260, 234 HIV-infected antiretroviral therapy (ART)-naive participants were randomized to receive tenofovir-emtricitabine and protease inhibitors or raltegravir and had HIV-1 RNA less than 50 copies/ml by week 24 and thereafter...
November 13, 2016: AIDS
https://www.readbyqxmd.com/read/27409415/severe-dyslipidemia-and-immune-activation-in-hiv-patients-with-dysglycemia
#14
Changzhong Jin, Shujing Ji, Tiansheng Xie, Stefan Höxtermann, Wolfgang Fuchs, Xiangyun Lu, Haibo Wu, Linfang Cheng, Adriane Skaletz-Rorowski, Norbert H Brockmeyer, Nanping Wu
BACKGROUND AND OBJECTIVE: Diabetes mellitus (DM) is common in human immunodeficiency virus (HIV)-infected patients. However, the relationship between dysglycemia, lipid metabolism, and immune activation in HIV patients is poorly understood. METHODS: We retrospectively analyzed the clinical data of 180 HIV patients, including 153 patients undergoing highly active antiretroviral therapy (HAART) and 27 HAART-naive patients. DM was defined as fasting serum glucose levels ≥126 mg/dl, and impaired fasting glucose (IFG) was defined as serum glucose levels of 101-125 mg/dl at two different time points...
September 2016: HIV Clinical Trials
https://www.readbyqxmd.com/read/27304841/effects-of-pitavastatin-on-lipid-profiles-in-hiv-infected-patients-with-dyslipidemia-and-receiving-atazanavir-ritonavir-a-randomized-double-blind-crossover-study
#15
RANDOMIZED CONTROLLED TRIAL
Asita Wongprikorn, Chonlaphat Sukasem, Apichaya Puangpetch, Pawin Numthavej, Ammarin Thakkinstian, Sasisopin Kiertiburanakul
BACKGROUND: Dyslipidemia as a risk factor of cardiovascular disease is common especially in HIV-infected patients who are using protease inhibitors (PIs) including atazanavir. Pitavastatin has less drug-drug interactions and demonstrable efficacy in decreasing lipid levels in non HIV-infected individuals. MATERIALS AND METHODS: This study was a randomized, double-blind, crossover study comparing the safety and efficacy of pitavastatin vs placebo in HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir (ATV/r)...
2016: PloS One
https://www.readbyqxmd.com/read/27270208/efavirenz-and-ritonavir-boosted-lopinavir-use-exhibited-elevated-markers-of-atherosclerosis-across-age-groups-in-people-living-with-hiv-in-ethiopia
#16
Rudolph L Gleason, Alexander W Caulk, Daniel Seifu, Julia C Rosebush, Alyssa M Shapiro, Matthew H Schwartz, Allison Ross Eckard, Wondwossen Amogne, Workeabeba Abebe
BACKGROUND: HIV patients on highly-active antiretroviral therapy (HAART) have shown elevated incidence of dyslipidemia, lipodystrophy, and markers of cardiovascular disease. Evidence is beginning to emerge that implicates efavirenz (EFV) as a potential mediator of early on-set cardiovascular disease. METHODS: Pediatric and adult HIV-infected HAART-naïve, EFV-treated, nevirapine (NVP)-treated, and ritonavir-boosted lopinavir (LPV/r)-treated subjects were recruited from Black Lion Hospital in Addis Ababa, Ethiopia...
September 6, 2016: Journal of Biomechanics
https://www.readbyqxmd.com/read/27188902/the-actn3-r577x-polymorphism-affects-the-lipid-profile-and-the-prognosis-of-nutritional-intervention-in-hiv-positive-patients
#17
Laura C R Aranalde, Bruna S Pederzoli, Thais Marten, Flavio C Barros, Rossana P Basso, Jussara M Silveira, Sandra C Valle, Simone Pieniz, Ronaldo C Araujo, Edgar J Paredes-Gamero, Ines Schadock, Augusto Schneider, Carlos C Barros
The hypothesis of the present study is that the polymorphisms in the APOC3, CEPT, ACE, and ACTN3 genes can affect the outcome of nutritional intervention and the plasma lipid profile of HIV+ patients. To test the hypothesis, genetic material was collected from buccal cells, and serum was collected for biochemical analysis. Sixty-five patients were analyzed. The incorporation of protease inhibitor (PI) was more frequent in women (77% vs 33% in men). Nutritional intervention improved anthropometric parameters independent of the genotype...
June 2016: Nutrition Research
https://www.readbyqxmd.com/read/26987376/rosuvastatin-vs-protease-inhibitor-switching-for-hypercholesterolaemia-a-randomized-trial
#18
RANDOMIZED CONTROLLED TRIAL
F J Lee, P Monteiro, D Baker, M Bloch, N Roth, R Finlayson, R Moore, J Hoy, E Martinez, A Carr
OBJECTIVES: The aim of the study was to compare the efficacy and safety of rosuvastatin initiation with those of switching of ritonavir-boosted protease inhibitors (PI/rs) in HIV-1-infected adults with hypercholesterolaemia and increased cardiovascular risk scores. METHODS: In this open-label, multicentre study, HIV-1-infected adults on PI/r-based therapy with viral load < 50 HIV-1 RNA copies/mL, fasting total cholesterol ≥ 5.5 mmol/L (both for ≥ 6 months) and elevated cardiovascular risk (Framingham score ≥ 8% or diabetes or family history), and not on lipid-lowering therapy, were randomized to open-label rosuvastatin 10 mg/day or to PI/r switching, both with standardized diet/exercise advice...
September 2016: HIV Medicine
https://www.readbyqxmd.com/read/26858314/lipid-changes-in-virologically-suppressed-hiv-infected-patients-switching-from-any-antiretroviral-therapy-to-the-emtricitabine-rilpivirine-tenofovir-single-tablet-gesida-study-8114
#19
Rosario Palacios, Marisa Mayorga, Isabel A Pérez-Hernández, Antonio Rivero, Alfonso Del Arco, Fernando Lozano, Jesús Santos
We carried out a retrospective, multicenter study of a cohort of 298 asymptomatic HIV-infected patients who switched from a regimen based on 2 nucleoside reverse transcriptase inhibitors + protease inhibitor (PI)/nonnucleoside reverse transcriptase inhibitor or ritonavir-boosted PI monotherapy to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) to analyze lipid changes. At 24 weeks, 284 (95.3%) patients were still taking the same regimen, maintaining similar CD4 counts as at baseline (651 versus 672 cells/mm(3), P = ...
May 2016: Journal of the International Association of Providers of AIDS Care
https://www.readbyqxmd.com/read/26648662/plasma-nitration-of-high-density-and-low-density-lipoproteins-in-chronic-kidney-disease-patients-receiving-kidney-transplants
#20
Ahmed Bakillah, Fasika Tedla, Isabelle Ayoub, Devon John, Allen J Norin, M Mahmood Hussain, Clinton Brown
BACKGROUND: Functional abnormalities of high-density lipoprotein (HDL) could contribute to cardiovascular disease in chronic kidney disease patients. We measured a validated marker of HDL dysfunction, nitrated apolipoprotein A-I, in kidney transplant recipients to test the hypothesis that a functioning kidney transplant reduces serum nitrated apoA-I concentrations. METHODS: Concentrations of nitrated apoA-I and apoB were measured using indirect sandwich ELISA assays on sera collected from each transplant subject before transplantation and at 1, 3, and 12 months after transplantation...
2015: Mediators of Inflammation
keyword
keyword
105481
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"